MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive ...

Mark T. Esser, a pharmaceutical researcher and executive, brings scientific expertise and leadership experience to his new ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

NEWPORT, Ky. (WXIX) - Wood Hudson Cancer Research Laboratory is launching its 2025 undergraduate research education program. FOX19 NOW’s Jason Maxwell has the story. See a spelling or ...

Li, president of Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

In 2024, my research suggests fewer than 15 approved drugs earned >$10bn of revenues, and <35 earned >$5bn. As such, it's possible Merck may struggle to grow its top line much, if at all ...

Dean Li, president, Merck Research Laboratories, said: “Elevated blood concentrations of Lp(a) provide a well-documented risk factor for atherosclerotic CVD… HRS-5346, an investigational oral small ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio-metabolic ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...

affecting as many as one in five adults globally,” Merck Research Laboratories President Dean Li, M.D., Ph.D., said in this morning’s release. “HRS-5346, an investigational oral small ...